Hypercalcemia
Clinical Snapshot
Hypercalcemia is an elevated serum calcium level, corrected for serum albumin — since roughly 40% of circulating calcium is protein-bound, total calcium falls when albumin is low even though the physiologically active ionized fraction has not changed. A practical bedside formula: corrected calcium (mmol/L) = measured total calcium (mmol/L) + [0.02 x (40 minus measured albumin in g/L)].[1] Two hormones, parathyroid hormone (PTH) and vitamin D, normally hold serum calcium within a narrow range (roughly 2.10-2.60 mmol/L): PTH raises serum calcium by stimulating osteoclastic bone resorption, increasing renal calcium reabsorption, and driving renal activation of vitamin D to its active form (calcitriol), which in turn increases intestinal calcium absorption.[2]
Hypercalcemia is staged by the corrected serum calcium level: mild under 3 mmol/L (under 12 mg/dL), moderate 3-3.5 mmol/L (12-14 mg/dL), and severe over 3.5 mmol/L (over 14 mg/dL).[3] This numeric staging matters for treatment decisions, but the level alone does not reliably predict how symptomatic a given patient will be. The rate at which calcium rises matters as much as the absolute level reached — the severity of symptoms is not always related to the degree of hypercalcemia but often instead reflects the rapidity of onset, and the onset of hypercalcemia can itself be genuinely insidious.[1] In practice, this means a patient with a chronically elevated but slowly progressive calcium from longstanding, mild primary hyperparathyroidism may be entirely asymptomatic at a level that would produce confusion or coma if reached rapidly from a malignant process — treat the trajectory, not only the number.
Primary hyperparathyroidism is the most common cause of hypercalcemia in ambulatory outpatients, typically producing a mild, slowly progressive elevation; it is covered in full in this platform's separate Hyperparathyroidism chapter and is deliberately not re-explained here. Malignancy is the most common cause in hospitalized and acutely unwell patients, typically producing a higher, more rapidly rising, and more symptomatic level.[4][2] Together, these two causes account for over 90% of all hypercalcemia.[4][2]
Recognize the Condition
Hypercalcemia affects roughly 1% of the general population, though the figure is far higher in specific clinical settings. It is the most frequent metabolic emergency in oncology, occurring in 10-40% of people with cancer over the course of their disease, most commonly with advanced disease — where its presence is itself a marker of poor prognosis (see Special Populations).[1] Tumours most often associated with malignancy-related hypercalcemia are multiple myeloma (40-50% of myeloma patients), breast cancer (over 20% of cancer-related hypercalcemia cases), and squamous-cell lung cancer (about 20%, occasionally adenocarcinoma, rarely small-cell); renal cell carcinoma and squamous-cell cancers of the head/neck and esophagus are also recognized associations. Hypercalcemia is rare or essentially never seen with prostate or colorectal cancer.[1]
Stones, bones, groans, and psychiatric overtones
This classic mnemonic organizes the presentation, though patients rarely display every feature at once, symptoms may be entirely absent at mild severity, and the onset can be genuinely insidious.[4][1]
Presentation by system
Renal ("stones")
- Polyuria and polydipsia, from impaired renal concentrating ability.
- Nephrolithiasis and, with chronic hypercalcemia, nephrocalcinosis.
- Dehydration, which is near-universal in symptomatic hypercalcemia and both a consequence of the polyuria and a driver of a worsening cycle — volume contraction reduces renal calcium clearance, which raises calcium further.
Skeletal ("bones")
- Bone pain, most often from local osteolytic metastasis or long-standing PTH-driven resorption.
- Osteoporosis and, in advanced primary hyperparathyroidism, osteitis fibrosa cystica.
Gastrointestinal ("groans")
- Anorexia, nausea, vomiting, and constipation are the most common GI complaints.
- Less commonly, peptic ulcer disease and acute pancreatitis.
Neuropsychiatric ("psychic groans" / "psychiatric overtones")
- A spectrum from mild impaired concentration and memory, fatigue, and lethargy at lower severity, through confusion, delirium (the single most frequent neurologic effect), and profound muscle weakness, to obtundation, seizures, psychosis, and coma at severe, rapidly rising levels.
- Hyporeflexia and myopathy.
Cardiac
- A shortened QT interval is the classic ECG finding; a prolonged PR interval and widened QRS complex are also seen.
- Bradycardia, and both ventricular and atrial arrhythmias — potentially fatal, and a particular risk if calcium rises quickly, especially in a patient also taking digoxin.
Risk Factors
Hypercalcemia is conventionally split into PTH-mediated and non-PTH-mediated causes — a distinction that maps directly onto the initial diagnostic test (see Assessment & Diagnosis).[2]
Causes, by mechanism
PTH-mediated
- Primary hyperparathyroidism — the most common outpatient cause; see this platform's separate Hyperparathyroidism chapter for full detail.
- Tertiary hyperparathyroidism, from parathyroid hyperplasia after chronic overstimulation (e.g., long-standing secondary hyperparathyroidism in chronic kidney disease).
- Familial hypocalciuric hypercalcemia — a calcium-sensing receptor mutation; distinguished from primary hyperparathyroidism by a low 24-hour urinary calcium.
- Lithium — genuinely pharmacist-relevant. Lithium raises the calcium set point at which PTH secretion is suppressed, so a higher-than-normal calcium is needed before the parathyroid gland "senses" adequate calcium and turns PTH secretion off; the result is a mild, PTH-mediated hypercalcemia that can persist for as long as lithium therapy continues.[2]
- Teriparatide and abaloparatide (PTH/PTH-related-peptide analogues used for osteoporosis) can produce a mild, expected, dose-related hypercalcemia.
Non-PTH-mediated
- Malignancy — the most common inpatient cause, through three distinct mechanisms:
- Humoral hypercalcemia of malignancy, from tumour secretion of parathyroid hormone-related protein (PTHrP), which mimics PTH's bone- and kidney-level effects without being detected by a standard PTH assay. This accounts for roughly 80% of malignancy-associated hypercalcemia and is classically associated with squamous-cell carcinomas (lung, head and neck, esophagus) and renal cell carcinoma.[1]
- Local osteolytic hypercalcemia, from direct bony metastasis and local osteoclast activation — classically breast cancer and multiple myeloma. The extent of metastatic disease does not correlate well with the calcium level reached.[1]
- Calcitriol-mediated hypercalcemia, from ectopic 1,25-dihydroxyvitamin D production by tumour cells — occurs rarely, most notably in lymphoma.[1][2]
- Vitamin D toxicity — a genuinely preventable, pharmacist-relevant cause, most often from excess over-the-counter vitamin D supplementation rather than prescription dosing. In suspected vitamin D toxicity, measure 25-hydroxyvitamin D specifically (not 1,25-dihydroxyvitamin D), since it is the markedly elevated storage form that confirms overdose.[4]
- Thiazide diuretics — another pharmacist-critical, drug-induced cause. Thiazides increase distal tubular calcium reabsorption, producing a mild hypercalcemia that should resolve once the drug is discontinued; persistent hypercalcemia after stopping a thiazide should prompt evaluation for an underlying process (often previously subclinical primary hyperparathyroidism) that the thiazide had simply unmasked.[4][2]
- Immobilization — increases osteoclastic and reduces osteoblastic activity; most clinically significant in a patient with an already high bone-turnover state (e.g., Paget disease, or a rapidly growing adolescent skeleton).[4]
- Granulomatous disease, classically sarcoidosis, also tuberculosis — activated macrophages within granulomas convert 25-hydroxyvitamin D to calcitriol independently of renal 1-alpha-hydroxylase regulation, driving the same calcitriol-mediated mechanism seen in lymphoma.[4][2]
- Other endocrinopathies — hyperthyroidism (increased bone turnover), adrenal insufficiency, and pheochromocytoma.[2]
- Milk-alkali syndrome, from excessive calcium carbonate intake (antacid or supplement) together with reduced renal calcium excretion.
Red Flags & Refer
Hypercalcemia can escalate from a laboratory abnormality to a true medical emergency — the criteria below identify when it has.
- Severe hypercalcemia (over 3.5 mmol/L) with significant neurologic symptoms — confusion, obtundation, seizure, or coma — or with a cardiac arrhythmia: this is a medical emergency requiring urgent, monitored treatment, not routine outpatient management.[3]
- A rapidly rising calcium level, regardless of the absolute value reached — because symptom severity tracks the rate of rise as much as the level itself, a rapid rise can be dangerous even before it reaches the numeric "severe" threshold, and demands the same urgency as a documented severe level.[1]
- Any hypercalcemia with a shortened QT interval and additional risk for a fatal arrhythmia — particularly in a patient also taking digoxin, where hypercalcemia increases digoxin toxicity risk at an otherwise unremarkable digoxin level.[1]
- Marked, symptomatic dehydration accompanying hypercalcemia — both need urgent correction together, since each worsens the other.
- New, unexplained hypercalcemia in a patient with known or suspected malignancy, or in an older adult with an atypical presentation (new confusion, constipation, or functional decline) — warrants prompt escalation for diagnostic workup rather than reassurance.
Assessment & Diagnosis
History and physical examination
- Directed at etiology: medication review (lithium, thiazides, vitamin D and calcium supplements, antacids, teriparatide/abaloparatide), immobility, known or suspected malignancy, family history, and symptoms from each system above.
- Assess hydration status directly — most hypercalcemic patients are volume-depleted.
- Obtain an ECG when clinically indicated — severe hypercalcemia, any symptomatic presentation, or concurrent digoxin therapy — looking for a shortened QT interval, a prolonged PR interval, a widened QRS complex, or bradyarrhythmia.[1]
Confirm and stage
Confirm with a corrected (albumin-adjusted) total calcium, or with an ionized calcium directly where available — ionized calcium is not affected by albumin and is the more reliable measure in a patient with significant hypoalbuminemia or a critical illness. Stage severity as mild, moderate, or severe (see Clinical Snapshot), and estimate the rate of rise from any prior calcium values on record.[1][3]
PTH — the key initial test
Measure intact PTH first, before further workup — it is the single test that most efficiently separates the two major diagnostic pathways.[2][4]
- PTH elevated, or inappropriately normal (i.e., not appropriately suppressed given the elevated calcium) points to a PTH-mediated cause — most often primary hyperparathyroidism. A 24-hour urinary calcium helps distinguish primary hyperparathyroidism (high urinary calcium) from the much rarer familial hypocalciuric hypercalcemia (low urinary calcium). See this platform's separate Hyperparathyroidism chapter for the full diagnostic and management pathway from this point.[2]
- PTH suppressed points to a non-PTH-mediated cause, most often malignancy, and directs further testing:
- PTHrP — order specifically when malignancy is suspected; an elevated level confirms humoral hypercalcemia of malignancy.[2][1]
- 25-hydroxyvitamin D — markedly elevated in vitamin D toxicity/excess supplementation.[4]
- 1,25-dihydroxyvitamin D (calcitriol) — elevated (with a normal or low 25-hydroxyvitamin D) in calcitriol-mediated hypercalcemia from lymphoma or granulomatous disease such as sarcoidosis.[2][4]
Supportive and additional testing
- Serum albumin — required to interpret total calcium correctly.[1]
- Alkaline phosphatase — usually elevated with increased bone turnover, except characteristically normal in multiple myeloma.[1]
- Serum chloride — may be elevated in primary hyperparathyroidism (an elevated chloride-to-phosphate ratio is a classic, if now rarely used, supportive finding).[1]
- BUN and creatinine — may be elevated from hypercalcemia-related renal impairment, and are also needed before any bisphosphonate dose (see Choose Initial Treatment).[1]
- Serum/urine protein electrophoresis, thyroid function testing, and imaging directed at a suspected malignancy where the cause remains unclear after initial workup.[2]
Treatment Targets
- Acutely lower serum calcium to a safe level and control symptoms — the immediate priority in any moderate-severe or symptomatic presentation.
- Restore intravascular volume, since dehydration both accompanies and perpetuates hypercalcemia.
- Identify and treat the underlying cause rather than treating the number in isolation — stopping a causative drug, treating the underlying malignancy, or referring for parathyroidectomy where appropriate.
- In malignancy-associated hypercalcemia specifically, situate acute treatment within the patient's overall goals of care rather than treating reflexively (see Special Populations).
- Avoid iatrogenic harm from treatment itself — volume overload from overly aggressive rehydration, hypocalcemia from bisphosphonate or denosumab overshoot, and renal toxicity from bisphosphonate therapy given without adequate hydration or in significant renal impairment.
Choose Initial Treatment
Escalate by severity: rehydration first, then a calcitonin bridge if urgent, then a bisphosphonate as the mainstay
Mild, asymptomatic hypercalcemia (under 3 mmol/L) hydration alone is often sufficient — increase oral fluid intake, hold any causative drug, and mobilize the patient; specific pharmacotherapy is not usually needed.[1]
Moderate-severe or symptomatic hypercalcemia begin with IV isotonic (0.9%) saline — this is the foundational first step for essentially every patient in this category, restoring volume and promoting renal calcium excretion while other therapies take effect. Most hypercalcemic patients are several litres behind in overall fluid balance; a typical regimen restarts at roughly 100-120 mL/hour IV (or by hypodermoclysis), adjusted downward for a patient with cardiac disease or heart failure risk, since additional volume — compounded by any drug-related fever — can precipitate decompensation. Adequate hydration alone can lower serum calcium by a median of about 0.25 mmol/L.[1][3]
Loop diuretics are not routinely recommended alongside rehydration — this is a genuine shift from older teaching. There is very little evidence supporting the efficacy or safety of furosemide for this purpose, and its routine addition risks worsening volume and electrolyte depletion rather than helping; reserve a loop diuretic for the specific situation of a patient who becomes volume-overloaded during rehydration, given only judiciously and after volume has already been repleted.[3][1]
Calcitonin — add for the first 24-48 hours when rapid lowering is needed (severe hypercalcemia, significant symptoms, or a rapidly rising level) while awaiting the delayed onset of a bisphosphonate. Calcitonin has a genuinely rapid onset (roughly 4 hours) but a short duration of action and is prone to tachyphylaxis with continued use — limit treatment to 48-72 hours, and always combine it with a bisphosphonate rather than relying on it alone.[3][1]
IV bisphosphonate therapy is the mainstay for moderate-severe or malignancy-associated hypercalcemia, once the patient is adequately hydrated with a satisfactory urine output — do not give a bisphosphonate before rehydration is underway.[1] Both agents have a delayed onset (calcium begins falling at roughly 48-72 hours) but a considerably more sustained effect than calcitonin.
- Zoledronic acid is generally preferred: 4 mg IV over no less than 15 minutes, following standard rehydration. Per the Canadian product monograph, dose reduction is not recommended for mild-to-moderate renal impairment specifically in tumour-induced hypercalcemia (unlike the separate bone-metastasis indication, which does use a renal-adjusted dose), but zoledronic acid is not recommended at all in severe renal impairment. At least one week should elapse before any retreatment, to allow the full response to the initial dose to develop.[5]
- Pamidronate is a reasonable alternative — 60-90 mg IV over 2-24 hours (longer infusion times reduce renal risk) — particularly when zoledronic acid is unsuitable or renal impairment is a specific concern; pre-treating with acetaminophen can reduce the flu-like "bisphosphonate fever" that both agents can cause. Pamidronate's effect typically lasts about 3-4 weeks, somewhat shorter than zoledronic acid's 4-6 weeks.[1]
Denosumab is the preferred option when IV bisphosphonate therapy has failed (refractory hypercalcemia) or when significant renal impairment makes a bisphosphonate relatively unsuitable — denosumab is not renally cleared and requires no renal dose adjustment. Note a genuine Canada/international guidance gap: the Canadian product monograph's approved indication is specifically hypercalcemia of malignancy refractory to IV bisphosphonate, narrower than more recent international guidance suggesting denosumab as a reasonable first-line alternative to a bisphosphonate more broadly. Dose: 120 mg SC on day 1, with additional 120 mg loading doses on days 8 and 15 of the first month, then 120 mg SC every 4 weeks thereafter. Monitor calcium closely in every patient, and especially in severe renal impairment or dialysis, where hypocalcemia risk is genuinely increased — check calcium within two weeks of dosing in this population.[6][3]
Dialysis (using a low- or no-calcium dialysate) is reserved for severe, refractory hypercalcemia, particularly with concurrent renal failure that limits the other options above, or when a large calcium load must be removed rapidly and other measures are failing.[2]
Non-Pharmacologic Treatment
- Mobilization — encourage and support ambulation wherever possible; immobility itself increases osteoclastic bone resorption and worsens hypercalcemia, especially in a patient with an already high bone-turnover state.[1]
- Increase oral fluid intake to roughly 2-3 litres per day as tolerated, for a patient able to take fluids by mouth and with mild or borderline hypercalcemia — this alone may be sufficient at this severity.[1]
- Stop or hold any drug contributing to hypercalcemia — thiazide diuretics, lithium (in consultation with the prescriber, given the need to weigh psychiatric stability), vitamin D and calcium supplements, calcium-containing antacids, and, less commonly, H2-receptor antagonists.[1]
- A low-calcium diet is not useful for the acute management of hypercalcemia — it is unpalatable, impractical, worsens nutritional status in an already unwell patient, and has essentially no role even in the specific setting of calcitriol-mediated hypercalcemia where dietary calcium restriction might seem intuitive.[1]
- Patient and caregiver education — for anyone at recognized risk (known malignancy, primary hyperparathyroidism, chronic lithium therapy, high-dose vitamin D supplementation), teach the early signs and symptoms of rising calcium to promote prompt recognition of an acute rise before it becomes severe.[1]
Special Populations
Malignancy-associated hypercalcemia and goals of care
Malignancy-associated hypercalcemia most commonly arises with advanced cancer and is itself a marker of poor prognosis.[1] Whether or not the underlying malignancy can itself be treated, every patient benefits from symptom-focused management of the hypercalcemia — education, hydration, and medication as above — but whether aggressive correction is appropriate at all depends on the patient's overall goals of care, not on the calcium level alone. An evident, treatable cause does not automatically mean treatment is indicated once the stage of the underlying disease is considered; this decision belongs to the patient (or substitute decision-maker) together with the treating team, ideally raised proactively rather than only in a crisis.[1] Pharmacists are well placed to flag when hypercalcemia treatment is being escalated (e.g., a second bisphosphonate cycle, then denosumab) without an apparent parallel conversation about the patient's overall trajectory and wishes.
Renal impairment
Renal impairment affects both the choice and the dosing of hypercalcemia therapy. Zoledronic acid requires no dose reduction for mild-moderate impairment in this specific indication but is not recommended in severe renal impairment; pamidronate remains an option with a longer infusion time. Denosumab requires no renal dose adjustment and is often the preferred choice once renal impairment is significant, but carries a genuinely elevated hypocalcemia risk in severe impairment or dialysis, requiring closer calcium monitoring.[5][6] Loop diuretics should still not be added routinely regardless of renal status, for the same reasons as in a patient with normal renal function.
Pregnancy and breastfeeding
Bisphosphonates (zoledronic acid, pamidronate) are contraindicated in pregnancy and breastfeeding per the Canadian product monograph, reflecting their long skeletal retention and theoretical risk to fetal bone development.[5] IV isotonic saline remains appropriate and safe. Hypercalcemia in pregnancy is uncommon and should prompt investigation for an underlying cause (most often primary hyperparathyroidism) and specialist involvement rather than routine bisphosphonate use.
Older adults
Older adults are both more likely to develop clinically significant hypercalcemia (higher background prevalence of malignancy and primary hyperparathyroidism, more frequent thiazide use) and more vulnerable to its cardiac and neuropsychiatric effects. Rehydration rate should be adjusted more conservatively in a patient with reduced cardiac reserve, and a new confusion, constipation, or functional decline in an older adult can be the presenting complaint rather than thirst or the classic symptoms.
Pediatrics
Hypercalcemia in children is uncommon and etiology differs meaningfully from the adult pattern (e.g., subcutaneous fat necrosis of the newborn, Williams syndrome, and immobilization-associated hypercalcemia in a rapidly growing, immobilized adolescent skeleton are more prominent). Dosing for calcitonin, bisphosphonates, and denosumab in children is not established in the sources for this chapter and requires pediatric endocrinology direction.
Monitoring & Follow-Up
- Recheck serum calcium, electrolytes, urea, and creatinine on day 3 after any IV bisphosphonate dose, and again as clinically indicated while calcium continues to trend toward normal.[1]
- Measure serum creatinine before every bisphosphonate dose; withhold or adjust further dosing if renal function has deteriorated from baseline.[5]
- Monitor serum calcium closely during and after calcitonin therapy, watching specifically for tachyphylaxis (a diminishing response) if treatment extends beyond 48-72 hours.
- After denosumab, check calcium within 2 weeks of each dose — more frequently, and for longer, in a patient with severe renal impairment or on dialysis, given the elevated hypocalcemia risk in this population.[6]
- Continuous ECG monitoring during treatment of any severe or symptomatic hypercalcemia, and in any patient also taking digoxin.
- Once the acute episode has resolved, follow up on the underlying cause identified — confirm a causative drug has genuinely been stopped (or reassessed with the prescriber), confirm oncology follow-up is in place for a malignancy-associated case, or refer for parathyroidectomy assessment where primary hyperparathyroidism was the cause (see the separate Hyperparathyroidism chapter).
Common Errors to Avoid
- Giving an IV bisphosphonate before the patient is adequately rehydrated — both reduces efficacy and increases renal toxicity risk.
- Adding a loop diuretic routinely alongside rehydration — outdated practice with little supporting evidence and a real risk of worsening volume/electrolyte depletion.
- Continuing calcitonin beyond 48-72 hours expecting a sustained effect — tachyphylaxis is expected, not a sign of an inadequate dose.
- Treating the numeric calcium level in isolation without considering the rate of rise — a rapidly rising level can be dangerous well before it reaches the "severe" numeric threshold.
- Missing a reversible drug-induced cause — thiazide diuretics, lithium, and over-the-counter vitamin D supplementation are common, genuinely modifiable contributors.
- Giving the standard 4 mg zoledronic acid dose in a patient with severe renal impairment, where it is not recommended, rather than considering pamidronate or denosumab instead.
- Assuming denosumab is first-line therapy in Canada — the Canadian product monograph's approved indication is specifically bisphosphonate-refractory hypercalcemia of malignancy, narrower than some international guidance.
- Escalating hypercalcemia treatment in advanced malignancy without an explicit goals-of-care conversation.
- Ordering PTHrP or vitamin D studies before checking PTH — PTH is the efficient first test that determines which further workup is actually needed.
- Attributing new confusion or functional decline in an older adult to "just getting older" rather than checking a calcium level.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Intravenous Fluids
Foundational first-line therapy for moderate-severe or symptomatic hypercalcemia — restores volume and promotes renal calcium excretion.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Sodium Chloride Injection USP 0.9% (normal saline) | Adults: Individualized IV infusion, adjusted to volume status and cardiac tolerance Children: Not established for routine pediatric use — individualize under pediatric endocrinology direction. | Volume overload, especially with cardiac disease or concurrent bisphosphonate-related fever | None significant at standard use | Roughly 100-120 mL/hour IV initially, adjusted to cardiac status and estimated fluid deficit; may itself lower calcium by a median of about 0.25 mmol/L |
Loop Diuretics
Not routinely recommended alongside rehydration — reserve for volume overload developing during treatment.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Furosemide | Adults: Standard diuretic dosing if genuinely indicated — not a routine addition Children: Not established for routine pediatric use — individualize under pediatric endocrinology direction. | Worsens volume and electrolyte depletion if used routinely or before adequate rehydration | Additive hypocalcemia risk with calcitonin or a bisphosphonate | Give only if the patient becomes volume-overloaded during rehydration, and only after volume has been repleted |
Calcitonin
Rapid-onset, short-duration bridge while awaiting bisphosphonate effect; always given together with a bisphosphonate, never as sole therapy beyond the acute window.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Calcitonin (salmon) | Adults: 4-8 international units/kg SC or IM every 6-12 hours, for 48-72 hours Children: Not established for routine pediatric use — individualize under pediatric endocrinology direction. | Flushing, mild nausea, crampy abdominal pain; small risk of hypersensitivity (salmon-derived) | Additive hypocalcemia risk with a bisphosphonate or denosumab | Onset about 4 hours. Limit treatment to 48-72 hours — tachyphylaxis is expected and is not an indication to increase the dose. |
Bisphosphonates, Intravenous
The mainstay of treatment for moderate-severe or malignancy-associated hypercalcemia. Give only after adequate rehydration with a satisfactory urine output. Delayed onset (roughly 48-72 hours) but a considerably more sustained effect than calcitonin.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Zoledronic acid | Adults: 4 mg IV over no less than 15 minutes, single dose Children: Not established for routine pediatric use — individualize under pediatric endocrinology direction. | Renal toxicity, hypocalcemia, acute-phase reaction/fever, osteonecrosis of the jaw and atypical femur fracture (with prolonged/repeated use) | Additive nephrotoxicity with other nephrotoxic drugs (NSAIDs, aminoglycosides); additive hypocalcemia risk with calcitonin, loop diuretics, or denosumab | No dose reduction needed for mild-moderate renal impairment in this specific (tumour-induced hypercalcemia) indication, but not recommended in severe renal impairment. At least 1 week before retreatment. Contraindicated in pregnancy and breastfeeding. |
| Pamidronate | Adults: 60-90 mg IV over 2-24 hours Children: Not established for routine pediatric use — individualize under pediatric endocrinology direction. | Bisphosphonate fever (premedicate with acetaminophen), renal toxicity, hypocalcemia, osteonecrosis of the jaw (with prolonged/repeated use) | Additive nephrotoxicity with other nephrotoxic drugs; additive hypocalcemia risk with calcitonin, loop diuretics, or denosumab | A reasonable alternative to zoledronic acid, particularly with renal impairment; longer infusion time reduces renal risk. Effect typically lasts about 3-4 weeks. Contraindicated in pregnancy and breastfeeding. |
RANKL Inhibitor
For hypercalcemia refractory to an IV bisphosphonate, or when significant renal impairment makes a bisphosphonate relatively unsuitable. No renal dose adjustment required, but hypocalcemia risk is genuinely elevated with severe renal impairment or dialysis.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Denosumab | Adults: 120 mg SC on day 1, with additional 120 mg doses on days 8 and 15 of month 1, then 120 mg SC every 4 weeks Children: Not established for routine pediatric use — individualize under pediatric endocrinology direction. | Hypocalcemia (closely monitor, especially with severe renal impairment/dialysis), hypophosphatemia, osteonecrosis of the jaw | Additive hypocalcemia risk with calcitonin, loop diuretics, or a bisphosphonate | Canadian-approved indication is specifically hypercalcemia of malignancy refractory to IV bisphosphonate. Check calcium within 2 weeks of dosing in severe renal impairment or dialysis. |
Glucocorticoids
For calcitriol-mediated hypercalcemia specifically (lymphoma, granulomatous disease such as sarcoidosis) — reduces macrophage/lymphocyte conversion of vitamin D to calcitriol. Not a substitute for a bisphosphonate in other hypercalcemia etiologies.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Dexamethasone | Adults: 4 mg SC or IV every 6 hours for 3-5 days Children: Not established for routine pediatric use — individualize under pediatric endocrinology direction. | Hyperglycemia, insomnia, mood changes, GI upset | Numerous — review the full medication list before starting | Reserve for a confirmed or strongly suspected calcitriol-mediated cause. |
References
- Hypercalcemia in Malignant Disease (Palliative Management) — Fraser Health Hospice Palliative Care Program, British Columbia. Approved by Hospice Palliative Care Clinical Practice Committee, November 24, 2006
- Hypercalcemia — StatPearls, StatPearls Publishing (Sadiq NM, Anastasopoulou C, Patel G, Badireddy M). StatPearls [Internet], updated May 7, 2024
- Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline — The Endocrine Society (El-Hajj Fuleihan G, Clines GA, Hu MI, et al.). J Clin Endocrinol Metab 2023;108(3):507-528
- A Practical Approach to Hypercalcemia — American Family Physician (Carroll MF, Schade DS). Am Fam Physician 2003;67(9):1959-1966
- ZOMETA (zoledronic acid for injection) Product Monograph — Novartis Pharmaceuticals Canada Inc., Health Canada. Date of Revision: December 5, 2014
- XGEVA (denosumab injection) Product Monograph — Amgen Canada Inc., Health Canada. Date of Revision: May 30, 2023
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.